Revance Therapeutics Inc (RVNC): RVNC reports 1Q24 results—reiterates 202...

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Revance Therapeutics Inc (RVNC)

Reply Private New

Keep Last Read

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	839
Posts	120661
Boards Moderated	13
Alias Born	09/05/2002

Re: marthambles post# 5619

Thursday, 05/09/2024 4:52:53 PM

Thursday, May 09, 2024 4:52:53 PM

RVNC reports 1Q24 results—reiterates 2024 guidance:

https://investors.revance.com/investors/Press-Releases/news-details/2024/Revance-Reports-First-Quarter-2024-Financial-Results-Provides-Corporate-Update/default.aspx

1Q24 financial highlights

• 1Q24 Daxxify sales were $22.1M, -8% QoQ — due to $2.0M of redeemed coupons and normal seasonality in the aesthetics business — and +44% YoY.

• 1Q24 Daxxify volume (units shipped) was +7% QoQ.

• 1Q24 dermal-filler sales were $29.6M, -14% QoQ and -2% YoY.

• Cash at 3/31/24 was $277.1M, a $23.2M increase relative to 12/30/23 due to $94.0M of net proceeds from the Mar 2024 public offering.

• 1Q24 non-GAAP operating expenses (excluding COGS) were $73.6M, consistent with the low end of RVNC’s full-year 2024 guidance of $290-310M.

2024 guidance

• RVNC re-iterated 2024 guidance for product revenue (Daxxify + RHA) of >=$280M.

• RVNC re-iterated 2024 guidance for non-GAAP operating expenses of $290-310M.

Note: An earlier version of this post (deleted) had a typo with respect to the 1Q24 non-GAAP operating expenses.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Keep Last Read

Replies (2) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent RVNC News

Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 01:24:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2024 01:29:09 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 11:32:37 AM
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm • PR Newswire (US) • 09/27/2024 01:17:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 11:15:36 AM
Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/16/2024 09:01:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:06:45 PM
Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 09/05/2024 09:27:28 PM
Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 09/05/2024 08:45:25 PM
Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 08/13/2024 01:29:06 PM
Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 08/12/2024 09:18:26 PM
Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. • PR Newswire (US) • 08/12/2024 07:18:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 01:20:58 PM
Crown Laboratories and Revance Announce Entry Into Merger Agreement • PR Newswire (US) • 08/12/2024 12:00:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 01:00:23 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:34:10 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:07:57 PM
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 08/08/2024 08:05:00 PM
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • Business Wire • 08/01/2024 08:05:00 PM
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/14/2024 08:05:00 PM
Revance to Participate in Upcoming Investor Conferences • Business Wire • 05/28/2024 08:05:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:33:08 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:08:10 PM
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update • Business Wire • 05/09/2024 08:06:00 PM
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia • Business Wire • 05/09/2024 08:05:00 PM

More RVNC News

InvestorsHub NewsWire

CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM

Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM

Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM

Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM

CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM

Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow